Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 5Terminated 4

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1

Conditions

Neoplasms 2Prostatic Neoplasms 1Multiple Myeloma 1Lymphoma 1Leukemia 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × plitidepsin × Clear all
NCT03117361 2020-12-02

Trial of Plitidepsin (AplidinĀ®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide

PharmaMar

Phase 2 Terminated
10 enrolled 37 charts
Plasma cell

Multiple Myeloma

NCT00780975 2020-11-24

A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer

PharmaMar

Phase 2 Terminated
8 enrolled 9 charts
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT03070964 2020-10-14

A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma

PharmaMar

Phase 2 Terminated
14 enrolled 21 charts
Lymphoid

Lymphoma

NCT00780143 2018-11-09

Clinical Study of Plitidepsin (AplidinĀ®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia

PharmaMar

Phase 1/2 Terminated
3 enrolled 6 charts
Other hematologic neoplasm

Leukemia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔